$879.87 Million in Sales Expected for STERIS plc (NYSE:STE) This Quarter

Wall Street analysts predict that STERIS plc (NYSE:STE) will report sales of $879.87 million for the current quarter, according to Zacks. Three analysts have made estimates for STERIS’s earnings. The lowest sales estimate is $870.80 million and the highest is $890.00 million. STERIS reported sales of $822.99 million during the same quarter last year, which indicates a positive year-over-year growth rate of 6.9%. The firm is expected to report its next quarterly earnings results on Wednesday, May 12th.

According to Zacks, analysts expect that STERIS will report full-year sales of $3.11 billion for the current fiscal year, with estimates ranging from $3.10 billion to $3.12 billion. For the next year, analysts forecast that the firm will post sales of $3.74 billion, with estimates ranging from $3.46 billion to $4.29 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow STERIS.

STERIS (NYSE:STE) last announced its quarterly earnings results on Tuesday, February 2nd. The medical equipment provider reported $1.73 EPS for the quarter, topping the Zacks’ consensus estimate of $1.52 by $0.21. The business had revenue of $808.90 million for the quarter, compared to analysts’ expectations of $794.08 million. STERIS had a return on equity of 14.44% and a net margin of 13.97%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.45 EPS.

STE has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 20th. Raymond James reiterated a “hold” rating on shares of STERIS in a research report on Wednesday, January 20th. Robert W. Baird lifted their price objective on STERIS from $200.00 to $230.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 13th. Finally, KeyCorp upgraded STERIS from a “sector weight” rating to an “overweight” rating and set a $224.00 price objective on the stock in a research report on Thursday, February 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $202.40.

In related news, Director David B. Lewis sold 1,560 shares of STERIS stock in a transaction that occurred on Tuesday, December 1st. The stock was sold at an average price of $193.79, for a total transaction of $302,312.40. Following the sale, the director now directly owns 8,244 shares in the company, valued at $1,597,604.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Julia Madsen sold 1,000 shares of STERIS stock in a transaction that occurred on Friday, January 8th. The shares were sold at an average price of $202.00, for a total value of $202,000.00. Insiders own 1.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Vantage Consulting Group Inc bought a new stake in STERIS in the fourth quarter worth $25,000. Exchange Traded Concepts LLC boosted its holdings in STERIS by 278.4% in the fourth quarter. Exchange Traded Concepts LLC now owns 140 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 103 shares in the last quarter. Newfound Research LLC bought a new stake in STERIS in the third quarter worth $26,000. Paces Ferry Wealth Advisors LLC bought a new stake in STERIS in the third quarter worth $30,000. Finally, Kinloch Capital LLC bought a new stake in STERIS in the fourth quarter worth $36,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

STERIS stock traded down $2.12 during trading hours on Thursday, reaching $173.50. The company had a trading volume of 12,249 shares, compared to its average volume of 584,329. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.64 and a quick ratio of 2.00. The company has a 50-day moving average price of $188.09 and a 200 day moving average price of $180.29. The firm has a market cap of $14.81 billion, a price-to-earnings ratio of 35.45 and a beta of 0.59. STERIS has a 12-month low of $105.69 and a 12-month high of $203.90.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 25th. Investors of record on Wednesday, February 24th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Tuesday, February 23rd. This represents a $1.60 annualized dividend and a dividend yield of 0.92%. STERIS’s dividend payout ratio is presently 28.37%.


STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

See Also: Can systematic risk be avoided?

Get a free copy of the Zacks research report on STERIS (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.